Trials / Completed
CompletedNCT02061670
Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma
A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Safety and Tolerability of Ragweed-SPIRE in Subjects With Asthma and Ragweed-Induced Rhinoconjunctivitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Circassia Limited · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether it is safe to administer Ragweed-SPIRE to subjects suffering from both ragweed allergy and asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ragweed-SPIRE | Intradermal injection |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2014-02-13
- Last updated
- 2015-01-21
Locations
5 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02061670. Inclusion in this directory is not an endorsement.